PeterStiegler earned his PhD in Molecular Biology at the University of Vienna Biocenter and performed a post doc at Thomas Jefferson University in Philadelphia PA. He since held positions in various operational functions in the Clinical Research arena with a focus in oncology early drug development at companies including EMD, Novartis Oncology Translational Medicine and Novartis Molecular Diagnostics.
After working at the Duke Clinical Research Institute focusing on biomarker development he worked as the Director of Clinical Operations at diagnostic development companies Prometheus Laboratories and Progenit